Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses
Immunologically inert or cold tumors pose a substantial challenge to the effectiveness of immunotherapy. The use of oncolytic viruses (OVs) to induce immunogenic cell death (ICD) in tumor cells is a well-established strategy for initiating the cancer immunity cycle (CIC). This process promotes the t...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1535647/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555089574068224 |
|---|---|
| author | Geofrey F. Soko Geofrey F. Soko Benson K. Kosgei Stephene S. Meena Stephene S. Meena Ying Jing Ng Huihui Liang Bing Zhang Qingjun Liu Tielong Xu Xinju Hou Xinju Hou Ray P. S. Han |
| author_facet | Geofrey F. Soko Geofrey F. Soko Benson K. Kosgei Stephene S. Meena Stephene S. Meena Ying Jing Ng Huihui Liang Bing Zhang Qingjun Liu Tielong Xu Xinju Hou Xinju Hou Ray P. S. Han |
| author_sort | Geofrey F. Soko |
| collection | DOAJ |
| description | Immunologically inert or cold tumors pose a substantial challenge to the effectiveness of immunotherapy. The use of oncolytic viruses (OVs) to induce immunogenic cell death (ICD) in tumor cells is a well-established strategy for initiating the cancer immunity cycle (CIC). This process promotes the trafficking and infiltration of CD8+ T cells into tumors, thereby eliciting a tumor-specific immune response. Despite the potential of OVs for handling cold tumors, clinical outcomes have fallen short of expectations. To better understand the obstacles faced by oncolytic virus immunotherapy (OVI), we would like to revisit the OV issue. Growing evidence indicates that limited intratumoral penetration and inadequate intratumoral distribution of OVs are critical factors contributing to the suboptimal response to OVI. Aberrant expressions of matrix proteins by cancer-associated fibroblasts (CAFs) alter the mechanical properties of the tumor extracellular matrix (ECM). This results in increased ECM desmoplasia and elevated intratumoral interstitial fluid pressure (IFP), creating physical barriers that impede the penetration and dissemination of OVs within tumors. This review explores the latest advancements in strategies designed to improve the intratumoral penetration of OVs to facilitate the penetration of tumor-infiltrating lymphocytes (TILs) into cold tumors. Additionally, we investigated current clinical trials and challenges associated with translating these strategies into clinical practice to improve patient outcomes. |
| format | Article |
| id | doaj-art-62f3c39fb08e428da8d722c3e827327d |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-62f3c39fb08e428da8d722c3e827327d2025-01-08T06:11:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15356471535647Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic virusesGeofrey F. Soko0Geofrey F. Soko1Benson K. Kosgei2Stephene S. Meena3Stephene S. Meena4Ying Jing Ng5Huihui Liang6Bing Zhang7Qingjun Liu8Tielong Xu9Xinju Hou10Xinju Hou11Ray P. S. Han12Jiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaOcean Road Cancer Institute, Dar es Salaam, TanzaniaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaOcean Road Cancer Institute, Dar es Salaam, TanzaniaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaThe Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, ChinaBiosensor National Special Laboratory & Key Laboratory for Biomedical Engineering of Education Ministry, Dept. of Biomedical Engineering, Zhejiang University, Hangzhou, ChinaEvidence-based Medicine Research Center, Jiangxi University of Chinese Medicine, Nanchang, ChinaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaDept. of Rehabilitation, Nanchang Hongdu Hospital of Chinese Medicine, Nanchang, ChinaJiangzhong Cancer Research Center, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China & Jiangxi Engineering Research Center for Translational Cancer Technology, Jiangxi University of Chinese Medicine, Nanchang, ChinaImmunologically inert or cold tumors pose a substantial challenge to the effectiveness of immunotherapy. The use of oncolytic viruses (OVs) to induce immunogenic cell death (ICD) in tumor cells is a well-established strategy for initiating the cancer immunity cycle (CIC). This process promotes the trafficking and infiltration of CD8+ T cells into tumors, thereby eliciting a tumor-specific immune response. Despite the potential of OVs for handling cold tumors, clinical outcomes have fallen short of expectations. To better understand the obstacles faced by oncolytic virus immunotherapy (OVI), we would like to revisit the OV issue. Growing evidence indicates that limited intratumoral penetration and inadequate intratumoral distribution of OVs are critical factors contributing to the suboptimal response to OVI. Aberrant expressions of matrix proteins by cancer-associated fibroblasts (CAFs) alter the mechanical properties of the tumor extracellular matrix (ECM). This results in increased ECM desmoplasia and elevated intratumoral interstitial fluid pressure (IFP), creating physical barriers that impede the penetration and dissemination of OVs within tumors. This review explores the latest advancements in strategies designed to improve the intratumoral penetration of OVs to facilitate the penetration of tumor-infiltrating lymphocytes (TILs) into cold tumors. Additionally, we investigated current clinical trials and challenges associated with translating these strategies into clinical practice to improve patient outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1535647/fullcold tumorstumor immune microenvironmentimmunotherapyoncolytic virusestumor-infiltrating immune cellstumor ECM barriers |
| spellingShingle | Geofrey F. Soko Geofrey F. Soko Benson K. Kosgei Stephene S. Meena Stephene S. Meena Ying Jing Ng Huihui Liang Bing Zhang Qingjun Liu Tielong Xu Xinju Hou Xinju Hou Ray P. S. Han Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses Frontiers in Immunology cold tumors tumor immune microenvironment immunotherapy oncolytic viruses tumor-infiltrating immune cells tumor ECM barriers |
| title | Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses |
| title_full | Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses |
| title_fullStr | Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses |
| title_full_unstemmed | Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses |
| title_short | Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses |
| title_sort | extracellular matrix re normalization to improve cold tumor penetration by oncolytic viruses |
| topic | cold tumors tumor immune microenvironment immunotherapy oncolytic viruses tumor-infiltrating immune cells tumor ECM barriers |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1535647/full |
| work_keys_str_mv | AT geofreyfsoko extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT geofreyfsoko extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT bensonkkosgei extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT stephenesmeena extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT stephenesmeena extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT yingjingng extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT huihuiliang extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT bingzhang extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT qingjunliu extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT tielongxu extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT xinjuhou extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT xinjuhou extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses AT raypshan extracellularmatrixrenormalizationtoimprovecoldtumorpenetrationbyoncolyticviruses |